Agios Pharmaceuticals presented the first data from the ongoing Phase 1 study evaluating single agent AG-881 in advanced glioma and other solid tumors. The data were featured in an oral presentation at the American Society of Clinical Oncology Annual Meeting. AG-881 is an investigational, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 and IDH2 enzymes, which was designed for enhanced brain penetrance for development in IDH-mutant glioma. “IDH mutant glioma is a distinct disease where patients are typically diagnosed in their thirties and forties and endure a deteriorating quality of life from the side effects associated with multiple rounds of surgery, radiation and chemotherapy and ultimately die of their disease,” said Ingo Mellinghoff, M.D., Memorial Sloan Kettering Cancer Center, an investigator for the study. “The AG-881 Phase 1 dose-escalation data are encouraging, as they demonstrate a favorable safety profile at lower dose levels and show signals of clinical activity that support further evaluation of the role of inhibiting mutant IDH in low-grade glioma.” “With no curative or approved targeted therapies for low-grade glioma and a poor long-term prognosis, we are committed to exploring the novel mechanism of action of our IDH inhibitors in this indication,” said Chris Bowden, M.D., chief medical officer at Agios. “Data from our ivosidenib and AG-881 Phase 1 trials and the ongoing perioperative study, combined with feedback from regulators and the neurology community, will inform our pivotal development plan.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.